Abstract:The emergence of drug resistance is a recurrent theme in targeted cancer therapies; thus, the understanding and conquering of drug resistance have become focal points in precision cancer medicine. While the biochemical and genetic mechanisms underlying drug resistance are diverse and complex, the state-of-art technologies (high-throughput sequencing, functional genomics, model systems, etc.) leading to the understanding of such mechanisms have been a consistent force driving the advancement of this field. Although many genes have been found to impact drug resistance, the limited convergence from multiple studies indicates that we are still at the beginning stage of unearthing the entire drug-resistance repertoire. New genomic technologies, preclinical models, and computational methodologies are poised to further accelerate the development of this new field. A major obstacle in precision cancer medicine is the inevitable resistance to targeted therapies. Tremendous effort and progress has been made over the past few years to understand the biochemical and genetic mechanisms underlying drug resistance, with the goal to eventually overcome such daunting challenges. Diverse mechanisms, such as secondary mutations, oncogene bypass, and epigenetic alterations, can all lead to drug resistance, and the number of known involved genes is growing rapidly, thus providing many possibilities to overcome resistance. The finding of these mechanisms and genes invariably requires the application of genomic and functional genomic approaches to tumors or cancer models. In this review, we briefly highlight the major drug-resistance mechanisms known today, and then focus primarily on the technological approaches leading to the advancement of this field. A major obstacle in precision cancer medicine is the inevitable resistance to targeted therapies. Tremendous effort and progress has been made over the past few years to understand the biochemical and genetic mechanisms underlying drug resistance, with the goal to eventually overcome such daunting challenges. Diverse mechanisms, such as secondary mutations, oncogene bypass, and epigenetic alterations, can all lead to drug resistance, and the number of known involved genes is growing rapidly, thus providing many possibilities to overcome resistance. The finding of these mechanisms and genes invariably requires the application of genomic and functional genomic approaches to tumors or cancer models. In this review, we briefly highlight the major drug-resistance mechanisms known today, and then focus primarily on the technological approaches leading to the advancement of this field. the CRISPR-Cas system functions as an adaptive immune system in bacteria and has been adapted to engineer mammalian genomes in an efficient manner. The CRISPR-Cas9 screen has become a powerful functional genetic screening approach suitable for mammalian genetic models, including human cancer cells and mouse models. a human cancer cell line panel established by the NCI Developmental Therapeutics Program to discover novel anticancer drugs; they are frequently studied cancer cell lines. a collection of ORF sequences are introduced into cancer cells through transfection in a multiwell format, and the cells are then exposed to single or combinatory agents before being tested for changes in their viability. an organ-bud grown in vitro, based on stem cells from a particular organ to form a 3D epithelial structure while retaining its tissue identity. a xenograft created when cancerous tissue from a patient's primary tumor is implanted directly into an immunodeficient mouse. These models avoid prior selection in tissue culture and may more closely mimic human cancer compared with cell line-derived xenografts. a member of the protein tyrosine kinases family, containing high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. similar to an ORF screen, but with the ORF libraries replaced by siRNA or shRNA libraries. a situation in which cells can tolerate the loss of one of two genes but their simultaneous inactivation causes lethality. Chemical synthetic lethality screens, drug enhancer screens, or ‘drop out’ screens are all intended to identify ways to achieve synthetic lethality. small-molecule drugs that inhibit tyrosine kinases. Tyrosine kinases are enzymes responsible for the activation of many proteins that can be regulated by phosphorylation in signal transduction cascades.

Albumin -conjugated drug is irresistible by single gene mutation of endocytic system: Verification by genome-wide CRISPR-Cas9 loss -of -function screens

KRAS-enhanced Macropinocytosis and Reduced FcRn-mediated Recycling Sensitize Pancreatic Cancer to Albumin-Conjugated Drugs

Tumor Exome Sequencing and Copy Number Alterations Reveal Potential Predictors of Intrinsic Resistance to Multi-Targeted Tyrosine Kinase Inhibitors

Albumin Binding Revitalizes NQO1 Bioactivatable Drugs As Novel Therapeutics for Pancreatic Cancer

Abstract 3624: Improved Intratumor Drug Delivery and Therapeutic Efficacy in Pancreatic Cancer by Albumin-Cisplatin Complex

Understanding the Genetic Mechanisms of Cancer Drug Resistance Using Genomic Approaches

Intravital Microscopy Reveals Endothelial Transcytosis Contributing to Significant Tumor Accumulation of Albumin Nanoparticles.

Abstract B040: In silico drug design using KRASG12C as a theranostic target for pancreatic cancer

FcRn overexpression in human cancer drives albumin recycling and cell growth; a mechanistic basis for exploitation in targeted albumin-drug designs

Macropinocytic dextran facilitates KRAS-targeted delivery while reducing drug-induced tumor immunity depletion in pancreatic cancer

Emerging Albumin-Binding Anticancer Drugs for Tumor-Targeted Drug Delivery: Current Understandings and Clinical Translation

Gemcitabine-Loaded Albumin Nanoparticle Exerts An Antitumor Effect on Gemcitabine-Resistant Pancreatic Cancer Cells Induced by MDR1 and MRP1 Overexpression in Vitro

Abstract 1940: Identifying resistant mechanisms to direct KRAS inhibitors in NSCLC

In Situ Drug-Receptor Binding Kinetics in Single Cells: a Quantitative Label-Free Study of Anti-Tumor Drug Resistance

Abstract 1942: Characterization of a panel of CRISPR/Cas9 engineered KRAS G12C inhibitor-resistant tumor models

Abstract 5839: Identification of low-dose ligand dependent drug-resistance in ALK/ROS1 positive NSCLC via CRISPR library screening

GP60 and SPARC as albumin receptors: key targeted sites for the delivery of antitumor drugs

Genome Editing of Mutant KRAS Through Supramolecular Polymer-Mediated Delivery of Cas9 Ribonucleoprotein for Colorectal Cancer Therapy.

Therapeutically reprogrammed nutrient signalling enhances nanoparticulate albumin bound drug uptake and efficacy in KRAS-mutant cancer

Targeted degradation of KRAS protein in non-small cell lung cancer: Therapeutic strategies using liposomal PROTACs with enhanced cellular uptake and pharmacokinetic profiles

Delivery of PTEN protein into tumor cells as a promising strategy for cancer therapy via active albumin nanoparticles: A hypothesis